

Dual Use Research of Concern at Colorado State University

Robert Ellis, PhD
CBSP, SM, DACVM

University Director of Biosafety and
Professor, Microbiology, Immunology and
Pathology

Colorado State University
Fort Collins, CO

What Research Is Subject to the Policy?

- **Research that directly involves any of the following 15 agents and toxins – except exclusions**
 - Avian influenza virus (highly pathogenic)**
 - Bacillus anthracis***
 - Botulinum neurotoxin (in any quantity)**
 - Burkholderia mallei***
 - Burkholderia pseudomallei***
 - Ebola virus**
 - Foot-and-mouth disease virus**
 - Francisella tularensis***
 - Marburg virus**
 - Reconstructed 1918 Influenza virus**
 - Rinderpest virus**
 - Toxin-producing strains of *Clostridium botulinum***
 - Variola major virus**
 - Variola minor virus**
 - Yersinia pestis***

CSU and DURC

- 2009 CSU added DURC question to Project Approval Request Form
- 2012 Two papers published on Gain of Function of H5N1 HPAIV
- 2012 USG Oversight policy on DURC
- 2014 Institutional policy for DURC
- 2015 CSU added more detailed query to PARF regarding DURC

- At CSU the “Institutional Review Entity” will be our existing IBC
- Institutional Contact for Dual Use Research (ICDUR) - VP for Research
- Investigators are notified of their responsibilities through the IBC protocol system
 - 1200 protocols per year
 - Checklist of the 7 “experimental effects” which defaults to “YES”

Issues to **Be** Resolved

- Agents that have potential DURC but are not on the list?
- Gain of Function (GOF) research for many agents (antimicrobial resistance, host range)?
- Research issues similar to the Australian “mouse pox” research (accidental GOF)?
- “How to” publications such as Botox in the milk supply?